Catalyst
Slingshot members are tracking this event:
Clearside Biomedical's (CLSD) Phase 3 SAPPHIRE trial of Suprachoroidal CLS-TA in Macular edema associated with retinal vein occlusion (RVO) Preliminary data due 4Q 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CLSD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 05, 2018
Occurred Source:
https://ir.clearsidebio.com/news-releases/news-release-details/clearside-biomedical-announces-sapphire-phase-3-study
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Sapphire, Suprachoroidal Cls-ta, Macular Edema After Retinal Vein Occlusion
